Roche reports a strong start in 2019 and raises the outlook for the full-year
Group sales increase 8% at constant exchange rates and 9% in Swiss francs
Pharmaceuticals Division sales up 10%, driven mainly by Ocrevus, Perjeta, Hemlibra and Tecentriq
Diagnostics Division sales grow 1%, with Molecular Diagnostics as main contributor
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
More News: Pharmaceuticals | Switzerland Health